~~<i id='AE339DB9D1'><strike id='AE339DB9D1'><tt id='AE339DB9D1'><pre id='AE339DB9D1'></pre></tt></strike></i>~~

Home» explore» entertainment

entertainment

author：focus 2025-10-09 05:38:25 Page View：65

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Software glitch causes Tandem insulin pump to shutdown, FDA warns
Next article： Continuity nursing helped my family in our darkest PICU moments

leisure time

Wildfire smoke exposes gaps in outdoor worker protections

ApersonwaitingforthesubwaywearsafilteredmaskassmokyhazefromwildfiresinCanadablanketsaneighborhoodinN

H5N1 communication has been strictly for the birds

JustinSullivan/GettyImagesWhenitcomestofederalagenciescommunicatingtothepublicaboutH5N1birdflu,itfee

Trump demands the U.S. pay no more for drugs than other countries … again

EthanMiller/GettyImagesWASHINGTON—FormerPresidentTrumpisbacktocampaigningfortyingMedicaredrugpricest

Study: Adult vaccinations pay for themselves in societal benefits

FREDERICJ.BROWN/AFPviaGettyImagesThenumberofchildrenwhoreceivedtheirroutinevaccinationsdeclineddurin